PET scan could predict best drug sequence for advanced breast cancer

NCT ID NCT06595563

Recruiting now Disease control Sponsor: Jules Bordet Institute Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special PET scan (HER2-PET) can help doctors decide which drug to use next in people with advanced HER2-positive breast cancer whose cancer has stopped responding to the drug trastuzumab deruxtecan (T-DXd). About 87 participants will get the scan and be grouped as 'positive' or 'negative' for HER2 activity. Those who are positive will receive a different targeted drug (T-DM1), while those who are negative will get standard care. The goal is to see if the scan can predict who will benefit from switching treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE METASTATIC BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE ADVANCED BREAST CANCER HER2-POSITIVE METASTATIC BREAST CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Institut Jules Bordet
RECRUITING

Anderlecht, Brussels Capital, 1070, Belgium

Contact Phone: •••-•••-•••• Email: •••••@•••••